Jane Street’s Repare Therapeutics RPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-278,304
| Closed | -$724K | – | 12790 |
|
|
2025
Q4 | $724K | Buy |
+278,304
| New | +$560K | ﹤0.01% | 6880 |
|
|
2025
Q2 | – | Sell |
-14,168
| Closed | -$14K | – | 10706 |
|
|
2025
Q1 | $14K | Buy |
+14,168
| New | +$17.1K | ﹤0.01% | 9171 |
|
|
2024
Q3 | – | Sell |
-11,886
| Closed | -$39.2K | – | 10288 |
|
|
2024
Q2 | $39.2K | Sell |
11,886
-5,048
| -30% | -$18K | ﹤0.01% | 8966 |
|
|
2024
Q1 | $79.8K | Sell |
16,934
-11,501
| -40% | -$73.7K | ﹤0.01% | 8612 |
|
|
2023
Q4 | $208K | Buy |
+28,435
| New | +$159K | ﹤0.01% | 8169 |
|
|
2023
Q3 | – | Sell |
-11,601
| Closed | -$123K | – | 9269 |
|
|
2023
Q2 | $123K | Buy |
11,601
+833
| +8% | +$8.58K | ﹤0.01% | 7913 |
|
|
2023
Q1 | $106K | Sell |
10,768
-17,429
| -62% | -$200K | ﹤0.01% | 8198 |
|
|
2022
Q4 | $415K | Buy |
+28,197
| New | +$422K | ﹤0.01% | 6462 |
|
|
2020
Q3 | – | Sell |
-25,139
| Closed | -$780K | – | 7811 |
|
|
2020
Q2 | $780K | Buy |
+25,139
| New | +$807K | ﹤0.01% | 4438 |
|
Jane Street's RPTX Position: Q1 2026 in Review
Jane Street sold out of Repare Therapeutics (RPTX) in Q1 2026, closing a stake of 278,304 shares — an estimated $724K sold.
Jane Street first reported a position in RPTX in Q2 2020 and held it in 9 quarters. The position peaked at $780K in Q2 2020. 0 funds tracked by Wall St. Rank hold RPTX as of Q1 2026.
- Jane Street reported no remaining Repare Therapeutics position as of Q1 2026 after selling out during the quarter.
- Jane Street sold 278,304 Repare Therapeutics shares in Q1 2026, an estimated $724K.
- Jane Street first reported a position in Repare Therapeutics in Q2 2020 and held it in 9 quarters.
- Jane Street's Repare Therapeutics position peaked at $780K in Q2 2020.
- 0 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.